Penumbra (NYSE:PEN) Director Sells $47,230.98 in Stock

Penumbra, Inc. (NYSE:PEN) Director Thomas Wilder sold 186 shares of the business’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $253.93, for a total transaction of $47,230.98. Following the sale, the director owned 186 shares in the company, valued at $47,230.98. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Thomas Wilder also recently made the following trade(s):

• On Tuesday, August 12th, Thomas Wilder sold 372 shares of Penumbra stock. The shares were sold at an average price of $240.16, for a total transaction of $89,339.52.

Penumbra Price Performance

Penumbra stock opened at $256.05 on Monday. The company has a quick ratio of 4.04, a current ratio of 6.75 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a 52-week low of $190.08 and a 52-week high of $310.00. The firm has a market cap of $9.99 billion, a PE ratio of 68.10, a price-to-earnings-growth ratio of 2.31 and a beta of 0.41. The company’s 50 day moving average is $257.64 and its two-hundred day moving average is $262.72.

Penumbra (NYSE:PEN) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.05. The business had revenue of $339.46 million for the quarter, compared to analyst estimates of $327.37 million. Penumbra had a return on equity of 11.55% and a net margin of 11.54%.The company’s revenue was up 13.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.64 earnings per share. Penumbra has set its FY 2025 guidance at EPS. On average, research analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PEN. Robert W. Baird lifted their price target on shares of Penumbra from $283.00 to $285.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Penumbra in a research report on Saturday, September 27th. William Blair upgraded shares of Penumbra to a “strong-buy” rating in a research note on Friday, July 18th. UBS Group set a $335.00 price target on Penumbra and gave the company a “buy” rating in a research note on Wednesday, July 30th. Finally, Evercore ISI began coverage on Penumbra in a report on Tuesday, September 2nd. They set an “outperform” rating and a $300.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $302.93.

Institutional Investors Weigh In On Penumbra

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Synergy Investment Management LLC purchased a new position in shares of Penumbra during the first quarter worth about $27,000. First Horizon Advisors Inc. grew its stake in Penumbra by 404.8% during the 1st quarter. First Horizon Advisors Inc. now owns 106 shares of the company’s stock worth $28,000 after buying an additional 85 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new position in Penumbra during the second quarter worth approximately $30,000. Parkside Financial Bank & Trust lifted its stake in Penumbra by 70.2% in the second quarter. Parkside Financial Bank & Trust now owns 160 shares of the company’s stock valued at $41,000 after buying an additional 66 shares during the last quarter. Finally, State of Wyoming acquired a new stake in shares of Penumbra in the second quarter valued at approximately $64,000. 88.88% of the stock is owned by hedge funds and other institutional investors.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.